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MaBACKGROUND Heart failure (HF) is increasing in prevalence and is a major cause of morbidity and mortality despite
advances in medical and device therapy. Autonomic imbalance, with excess sympathetic activation and decreased vagal
tone, is an integral component of the pathophysiology of HF.
OBJECTIVES The INOVATE-HF (Increase of Vagal Tone in Heart Failure) trial assessed the safety and efficacy of vagal
nerve stimulation (VNS) among patients with HF and a reduced ejection fraction.
METHODS INOVATE-HF was a multinational, randomized trial involving 85 centers including patients with chronic HF,
New York Heart Association functional class III symptoms and ejection fraction #40%. Patients were assigned to device
implantation to provide VNS (active) or continued medical therapy (control) in a 3:2 ratio. The primary efficacy endpoint
was composite of death from any cause or first event for worsening HF.
RESULTS Patients (n ¼ 707) were randomized and followed up for a mean of 16 months. The primary efficacy outcome
occurred in 132 of 436 patients in the VNS group, compared to 70 of 271 in the control group (30.3% vs. 25.8%; hazard
ratio: 1.14; 95% confidence interval: 0.86 to 1.53; p ¼ 0.37). During the trial, the estimated annual mortality rates
were 9.3% and 7.1%, respectively (p ¼ 0.19). Quality of life, New York Heart Association functional class, and
6-min walking distance were favorably affected by VNS (p < 0.05), but left ventricular end-systolic volume index
was not different (p ¼ 0.49).
CONCLUSIONS VNS does not reduce the rate of death or HF events in chronic HF patients. (INcrease Of VAgal TonE in
CHF [INOVATE-HF]; NCT01303718) (J Am Coll Cardiol 2016;68:149–58) © 2016 by the American College of Cardiology
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EF = ejection fraction
HF = heart failure
KCCQ = Kansas City
Cardiomyopathy Questionnaire
LVESVi = left ventricular end-
systolic volume index
NYHA = New York Heart
Association functional class
VNS = vagus nerve stimulation
Gold et al. J A C C V O L . 6 8 , N O . 2 , 2 0 1 6
Vagus Nerve Stimulation in Heart Failure J U L Y 1 2 , 2 0 1 6 : 1 4 9 – 5 8
150H eart failure (HF) remains an impor-tant public health problem that isincreasing in incidence and preva-
lence (1–3). It is the leading cause of hospital-
ization in adults in the United States despite
advances in the pharmacologic- and device-
based therapies over the past several de-
cades, and is still associated with a markedly
reduced survival. Given the increasing
burden of HF, there has been renewed effort
towards finding innovative treatments; how-
ever, only a few new pharmacologic treat-
ments have been shown effective for HF in
the last 10 years (4–6). As a result, concomi-tant device therapy has received increasing attention
in HF (7), and autonomic modulation is an important
target (8–10). It has long been recognized that the
autonomic nervous system becomes imbalanced in
HF, with withdrawal of parasympathetic tone and
increased activation of sympathetic nervous system
(8–10). Beta blockers are a mainstay of current treat-
ment and inhibit excess sympathetic stimulation.
However, to date, pharmacologic interventions that
increase parasympathetic tone and thus restore auto-
nomic balance (11,12) are limited. In contrast, there are
many device-based approaches under development
that modulate autonomic activity (13,14), including
vagus nerve stimulation (VNS) (15,16), spinal cord
stimulation (17,18), and baroreceptor activation (19).SEE PAGE 159VNS is the most-studied device-based therapy for
autonomic modulation in HF. However, no pivotal
study of VNS or other device-based autonomic mod-
ulation therapy has been performed to evaluate these
therapies on clinical morbidity and mortality.
Accordingly, the Increase of Vagal Tone in Heart
Failure (INOVATE-HF) trial was undertaken to assess
the impact of VNS in HF.
METHODS
STUDY DESIGN AND OVERSIGHT. The INOVATE-HF
study was an international, randomized, open-label
clinical trial. The trial was designed by the Steering
Committee and sponsored by BioControl Medical
(B.C.M.) Ltd. (Yehud, Israel). BioControl was respon-
sible for trial execution and monitoring (20). The trial
protocol was approved by the institutional review
board at each participating center, and all patients
provided written informed consent to participate.
The study results were analyzed independently
by North American Science Associates (NAMSA, Min-
neapolis, Minnesota). Details of the trial design have
been published previously (20).PATIENTS
Eligible patients were 18 years of age or older, with
New York Heart Association (NYHA) functional class
III symptoms and on stable medical therapy recom-
mended by current guidelines (1,3). Subjects were
required to have a left ventricular ejection fraction
(EF) #40% and a left ventricular end-diastolic diam-
eter of 50 to 80 mm. The exclusion criteria included
myocardial infarction or acute coronary syndrome in
the preceding 30 days, cardiac surgery in the pre-
ceding 6 months, chronic atrial fibrillation, and se-
vere liver or renal failure. Patient enrollment began in
April 2011. An amendment to the protocol to allow
patients with pre-existing cardiac resynchronization
therapy (CRT) but persistent NYHA functional class III
symptoms (i.e., nonresponders to CRT) was approved
by regulatory authorities in August 2012 and such
patients were enrolled from October 2012. Patients
were randomly assigned in a 3:2 ratio to have im-
plantation of the VNS system (active) in addition to
continued medical therapy or medical therapy alone
(control). Randomization was assigned electronically
and stratified according to sex and presence of CRT.
VNS DEVICE IMPLANTATION. Patients randomized
to VNS stimulation underwent implantation of a
BioControl CardioFit system as previously described
in detail (20). The procedure included placement of a
standard transvenous lead into the right ventricle for
sensing ventricular activation and a nerve stimula-
tion cuff on the right vagus nerve. The leads were
tunneled and connected to a pulse generator that was
placed in the right infraclavicular space.
After a 1-month healing period, patients under-
went multiple scheduled visits over a 4-week period,
during which time the stimulation output was grad-
ually increased with a goal of achieving current of 3.5
to 5.5 mA. In the control group, pre-planned study
visits were also scheduled during this period so that
the number of contacts with the study team could be
roughly equivalent with the VNS group. Study visits
in both groups were then performed every 3 months
through 18 months and then every 6 months for the
duration of the trial. At the 3-, 6-, and 12-months
visits, echocardiography, 6-min hall walk, NYHA
functional class assessment, and a quality-of-life
questionnaire were performed in addition to routine
evaluation. Echocardiographic measures were per-
formed by a core lab, although this was not used for
inclusion in the trial.
OUTCOME MEASURES. The primary efficacy
endpoint was the combination of death from any
cause or first event attributed to worsening HF. An HF











3 MONTH FOLLOW UP VISITS N=581
6 MONTH FOLLOW UP VISITS N=520







27 exited prior to implant:
2 deaths 





N = 71 Other Active subject exits:
60 deaths
10 due to clinical status
(7 VAD, 3 heart transplant)
1 explanted (infection)
N = 46 Control subject exits:
28 deaths
14 elective exits
2 due to clinical status (VAD)
1 lost  to follow up
1 investigator withdrew due to
       non compliance
CONTROL
N=271
The distribution and status of patients in the 2 arms of the trial are depicted. After the 12-month visit, patients were followed every 3 months until
18 months, then every 6 months thereafter until study closure.
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151event occurred when the subject had signs or symp-
toms of worsening HF and received an augmented
HF regimen for which a hospitalization was consid-
ered necessary, or if they received intravenous
decongestive therapy in the absence of an inpatient
hospitalization. All events were adjudicated based on
pre-specified definitions per a charter developed by
an independent clinical events committee. The first
co-primary safety objective was to demonstrate >75%
freedom from procedure and system-related compli-
cation through 90 days post-implantation (VNS group
only) with 95% confidence. The second co-primary
safety objective involved a comparison of time to
first event of death or complications from any cause
through 1 year between the 2 study arms.
The pre-specified secondary outcomes included
the following measured at the 12-month visit: changein NYHA functional class, change in 6-min hall walk
distance, echocardiographic core lab measured
change in left ventricular end-systolic volume index
(LVESVi) and changes in the Kansas City Cardiomy-
opathy Questionnaire (KCCQ) score.
STATISTICAL ANALYSIS. The study size and dura-
tion were event driven. To provide at least 80%
power, the study was designed to continue until the
accumulation of 376 primary efficacy events and 437
second co-primary safety events. The analysis of the
primary efficacy end point had 3 planned interim
analyses for futility at 0.333, 0.556, and 0.778 of the
total number of planned events (376). Baseline char-
acteristics were summarized as means and SDs for
continuous variables and as counts and percentages
for categorical variables and were compared with the
use of 2-sample Student t tests and chi-square (or





(n ¼ 436) p Value
Age, yrs 60.9  11.2 61.7  10.5 0.32
Male 219 (80.8%) 339 (77.8%) 0.38
Duration of heart failure, yrs 7.07.7  5.73 7.64  6.59 0.22
Heart failure etiology (ischemic) 173 (63.8%) 255 (58.5%) 0.19
Type 2 diabetes 91 (33.6%) 167 (38.3%) 0.23
Creatinine, mg/dl 1.3  0.5 1.2  0.5 0.82
Heart rate, beats/min 71.4  11.5 72.5  12.2 0.20
QRS duration non-CRT subjects, ms 108.6  21.1 111.2  24.4 0.23
QRS duration $ 120, ms 130 (48.0%) 210 (48.2%) 1.00
6-min hall walk distance, m 317.0  178.4 304.1  111.5 0.29
Body mass index, kg/m2 30.6  6.4 30.4  6.1 0.68
Blood pressure systolic, mm Hg 118.6  18.5 117.7  17.4 0.51
Blood pressure diastolic, mm Hg 72.5  10.3 71.7  10.9 0.33
Quality-of-life score (KCCQ score) 52.2  21.8 51.6  20.7 0.74
Left ventricular function
Left ventricular ejection fraction, % 25.2  7.3 23.9  6.7 0.02
Left ventricular end systolic volume index 100.6  40.5 106.0  41.8 0.11
Left ventricular end diastolic volume index 131.7  43.1 136.4  44.6 0.19
Concomitant device
CRT-pacer 5 (1.8%) 7 (1.6%) 1.00
CRT-defibrillator 90 (33.2%) 138 (31.7%) 0.73
Pacemaker 2 (0.7%) 4 (0.9%) 1.00
Defibrillator 127 (46.9%) 215 (49.3%) 0.58
Medication at baseline
Beta-blocker use 251 (92.6%) 409 (93.8%) 0.56
ACE-I or ARB use 246 (90.8%) 383 (87.8%) 0.31
Aldosterone Antagonist use 163 (60.1%) 259 (59.4%) 0.94
Diuretic agent use 205 (75.6%) 336 (77.1%) 0.69
Values are mean  SD or n (%). There were no significant between-group differences at baseline except for left
ventricular ejection fraction (p ¼ 0.02). Data were missing for the following characteristics: duration of heart
failure (for 1 patient in the active group), creatinine (for 2 patients in the control group and for 1 patient in the
active group), 6-min hall walk distance (for 2 patients in the control group and for 15 patients in the active group),
quality-of-life score (KCCQ score) (for 1 patient in the control group and for 4 patients in the active group), left
ventricular ejection fraction (for 28 patients in the control group and for 45 patients in the active group), left
ventricular end systolic volume index (for 28 patients in the control group and for 45 patients in the active group),
left ventricular end diastolic volume index (for 28 patients in the control group and for 44 patients in the active
group).
ACE-I ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; CRT ¼ cardiac
resynchronization therapy; KCQC ¼ Kansas City Cardiomyopathy Questionnaire; VNS ¼ vagus nerve stimulation.
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152Fisher exact) tests, respectively. The p values for
time-to-event analyses, hazard ratios (HRs) for
treatment effects, and 95% confidence intervals (CIs)
calculated from Cox proportional hazards models.
Interactions between treatment effects and subgroup
levels were tested for in Cox models that included
treatment and subgroup main effects and interaction
terms. Time-to-event curves were estimated with the
use of the Kaplan–Meier method. Changes in NYHA
functional class from baseline to 12 months were
analyzed with the use of an ordered logistic-
regression model, providing a p value for difference
between the control and VNS arms. The changes in
secondary outcomes other than NYHA functional
class were analyzed using 2 (VNS vs. control) by 2(baseline vs. follow-up) repeated measures analysis
of variance that included the treatment group by time
interaction. All p values in the efficacy analysis were
2-sided. The p values were not adjusted for multi-
plicity or interim looks.
RESULTS
PATIENT ENROLLMENT AND FOLLOW-UP. Begin-
ning in April 2011, patients were enrolled at 85 centers
in the United States, Europe, and Israel. There were
707 subjects who underwent randomization (436 pa-
tients to VNS and 271 to control) (Figure 1). On
December 15, 2015, the study was stopped by the
Steering Committee on the recommendation of the
independent Data and Safety Monitoring Board after
the second planned interim analysis, on the basis of
futility. At the date of study closure, the mean follow-
up period was 16 months (range: 0.1 months to 52
months). The study-visit compliance rate among pa-
tients was 98%; a total of 3,521 of the 3,599 required
study visits were completed.
PATIENT CHARACTERISTICS. The baseline charac-
teristics of the patients who were randomized are
shown in Table 1. This was a group of patients with
chronic HF, with a mean duration of symptoms of
approximately 7 years. The clinical characteristics
were generally similar between groups, except that
the left ventricular EF was lower in the VNS group.
More than 80% of patients had cardiac implantable
electronic devices, including approximately one-third
with CRTs.
EFFICACY OUTCOMES. The mean stimulation cur-
rent was 3.9  1.0 mA at the 6-month follow-up visit,
with 73% of patients achieving the goal of $3.5 mA.
The primary efficacy endpoint, death from any cause
or first event for worsening HF, occurred in 132 of 436
(30.3%) patients in the VNS group, as compared with
70 of 271 (25.8%) in the control group (HR with VNS,
1.14; 95% CI: 0.86 to 1.53; p ¼ 0.37). The survival
curves for the 2 groups are shown in Figure 2A. The
composition of the 202 first primary endpoint events
in this trial included 36 deaths, 155 HF hospitaliza-
tions, and 11 nonhospitalized HF events. Although
only the first HF episode or death contributed to the
composite endpoint, 53 patients had 2 events, 24 had
3 events, and 23 had 4 or more over the course of the
study. During the trial, 62 VNS patients (14.2%) died
compared with 28 control patients (10.3%) for esti-
mated annual mortality rates of 9.3% and 7.1%,
respectively (p ¼ 0.19) (Figure 2B). The cause of death
was adjudicated by the Clinical Events Committee,
with no significant differences in the proportion of
deaths between groups (Online Table 1).
































































































Death from Any Cause
A
B
(A) The Kaplan-Meier curves for the composite outcome of death from any cause or a
worsening heart failure event. (B) The Kaplan-Meier curves for death from any cause.
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153The pre-specified secondary endpoint analyses
included the change from baseline of 4 parameters to
be measured at the 12-month visit: 6-min hall walk
distance, KCCQ quality-of-life score, NYHA functional
class, and echocardiographic LVESVi. Of the 707 pa-
tients in the trial, there were 403 patients (57%) who
were in the trial long enough to complete a 12-month
follow-up visit; of these subjects, 391 (97%)
completed this visit, although not all endpoints could
be collected, for instance, due to technical quality of
echocardiograms. The 6-min hall walk distance
increased an average of 28.2 m in the VNS group
whereas it decreased 4.6 m in the control group
(p < 0.01). The KCCQ quality-of-life score increased
an average of 11.2 points in the VNS group compared
with 6.9 points in the control group (p < 0.01). The
LVESVi decreased 5.4 ml/m2 in the VNS group
compared with a decrease of 2.8 ml/m2 in the control
group (p ¼ 0.49). The results of these measurements
are shown in Figure 3. Finally, the distribution of
change of NYHA functional class differed with more
patients improving in the VNS group (p < 0.01)
(Figure 4). There were 520 patients (74% of the
cohort) who completed the 6-month follow-up visit
when these same endpoints were measured. These
data are depicted in Figures 3 and 4 and show similar
results qualitatively to the 12-month data.
SUBGROUPS. The effects of treatment on 6 pre-
specified subgroups for the primary efficacy com-
posite outcome are shown in the Central Illustration.
The only significant treatment by subgroup interac-
tion was for sex with worse outcomes with VNS
among female patients (p ¼ 0.03). However, as ex-
pected, there were many differences in baseline
characteristics between male and female patients. For
instance, women were younger, more likely to have a
nonischemic etiology of HF, smaller left ventricular
volumes, and shorter QRS durations (Online Table 2).
Given these differences in characteristics, a multivar-
iate analysis of the primary efficacy endpoint was
performed. This showed that sex was not an indepen-
dent predictor of outcome (p ¼ 0.17) (Online Table 3).
SAFETY. Among the 390 implanted patients, there
were 46 complications in 37 patients by 90 days. The
rate of freedom from procedure and system-related
events was 90.6% (95% CI: 87.7% to 93.5%; p < 0.01
for excluding a rate #75%). Thus, this result met the
first co-primary safety endpoint. The second co-
primary endpoint was a comparison between groups
of the composite endpoint of mortality of any-cause
or all-cause complications. There was no difference
between groups (HR with VNS: 1.07; 95% CI: 0.84 to
1.38; p ¼ 0.57) (Online Figure 1).DISCUSSION
INOVATE-HF is the first adequately powered, pivotal
study to assess the effect of device-based autonomic
modulation on outcome parameters in patients with
HF with a reduced EF. The primary results of this
study show that VNS was not effective for reducing
the rate of death from any cause or HF events.








Change from Baseline to 6 Month Follow-Up Change from Baseline to 12 Month Follow-Up
6MHW (m) KCCQ score LVESVi (ml/cm2) 6MHW (m) KCCQ score LVESVi (ml/cm2)
p<0.01 p=0.04 p=0.38 p<0.01 p<0.01 p=0.49
Control VNS
Data shown are mean  standard error of the mean. KCCQ ¼ Kansas City Cardiomyopathy Questionnaire; LVESVi ¼ left ventricular end-systolic
volume index; VNS ¼ vagus nerve stimulation; other abbreviation as in Figure 1.
FIGURE 4 Change of New York Heart Association Functional Class From Baseline at
























Baseline to 6 Month Follow-Up
p<0.01
Baseline to 12 Month Follow-Up
P=0.01
NYHA Changes Over Time
Paired data for the VNS and control groups at baseline and at 6-month follow-up (N ¼ 317
for VNS, N ¼ 194 for control) are shown on the left. The paired data at 12 months (N ¼ 243
for VNS, N ¼ 142 for control), which was a predefined secondary endpoint, are shown on
the right. Data were missing at 6 months for 4 VNS and 5 control patients, and at 12
months for 1 VNS and 5 control patients. Abbreviation as in Figure 3.
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154Moreover, VNS did not promote reverse remodeling
in this population. In contrast to the lack of benefit for
reducing clinical events, there were significant im-
provements in 6-min hall walk duration, NYHA
functional class, and quality-of-life measures.
It is well established that autonomic imbalance is
an important component of the adverse pathophysi-
ologic changes associated with chronic HF, so this has
been a target of many new therapies (21–23). VNS is the
best studied of such therapies (13–15). It has been used
for many years for the treatment of epilepsy (24) and
depression, and long-term safety and tolerability are
well established. However, in comparison to the well-
known effects of the sympathetic nervous system, the
role of the parasympathetic nervous system in the
pathophysiology of HF is less well understood. Pre-
clinical studies demonstrated the benefit of VNS to
reduce mortality, improve cardiac function, and
decrease inflammation in a variety of animal models
of HF (8–10). Indeed, the anti-inflammatory effects of
VNS after ischemia and reperfusion injury are
accompanied by a reduction in the number of macro-
phages and apoptotic cells that is paralleled by
decreased levels of circulating pro-inflammatory
cytokines (25). This has been referred to as the
“cholinergic anti-inflammatory reflex” (26). The po-
tential deleterious effects of VNS in the heart include
CENTRAL ILLUSTRATION Vagus Nerve Stimulation in Heart Failure: Univariate Predictors of
Primary Outcome Events
Gold, M.R. et al. J Am Coll Cardiol. 2016;68(2):149–58.
Forest plots of the pre-specified subgroups are shown. 6MHW ¼ 6-min hall walk; CRT ¼ cardiac resynchronization therapy; HF ¼ heart failure; HR ¼ hazard ratio;
int. p ¼ interaction p value for each pair of subgroups.
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155bradycardia, as well as potential negative inotropic
effects mediated through the M2 muscarinic receptor.
Based on the encouraging results noted previously,
a number of clinical studies of VNS were initiated
(27). A nonrandomized pilot study of 32 patients
implanted with the CardioFit system as used in the
present study showed improved quality of life andleft ventricular (LV) systolic function which was
maintained over long-term follow-up (14). More
recently, 2 randomized trials of 6-month duration
were performed using other VNS systems. NECTAR-
HF (NEuroCardiac TherApy foR Heart Failure Study)
(15) was a double-blinded, randomized study of 96
patients that compared VNS to medical therapy. The
Gold et al. J A C C V O L . 6 8 , N O . 2 , 2 0 1 6
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156primary endpoint of the trial was the change in LV
end-systolic diameter, which did not improve with
VNS. However, there was a significant improvement
in quality of life. ANTHEM-HF (Autonomic Neural
regulation THerapy to Enhance Myocardial function
in Heart Failure) (16) was an open-label study of 60
patients randomized to right- or left-sided VNS. Both
arms of this study showed significantly improved
echocardiographic measures of reverse remodeling.
The INOVATE-HF study adds importantly to our
knowledge of VNS therapy. Patients were followed for
up to 4.3 years with a mean follow-up 16 months,
compared with the short-term follow-up (6 months)
of other randomized trials of VNS. The long-term
treatment with chronic VNS in HF patients appears
to be safe, and it is consistent with the safety profile
of VNS for other indications. Finally, we chose effi-
cacy endpoints (mortality and HF events) which have
been used in many seminal pivotal HF trials. Despite
improvements in quality of life and functional status,
VNS did not improve these “hard” outcomes.
STUDY LIMITATIONS. One limitation of the study
design is the lack of blinding and a sham control
group. However, VNS often leads to minor side effects
so that it is not possible to ensure patient blinding.
For instance, the NECTAR-HF study, which is the only
VNS trial with an implanted and unstimulated control
group, blinding was not successful (15). In the active
group receiving VNS, 77.2% of patients believed they
were in the active arm compared with 7.0% who
believed they were in the control arm (blinding
index ¼ 0.70). Further, the use of sham implants is
more appropriate when the follow-up period is short
so that the control patients can be crossed over to
active treatment (28). INOVATE-HF was designed
to evaluate long-term outcomes and it was believed
to be inappropriate to expose the control group to the
risks of implantation but leaving the device inactive
for periods that could be several years.
We previously hypothesized (13,29) that the
average stimulation current may have been inade-
quate (or too low) to achieve a response with VNS in
the NECTAR-HF trial (15) (1.4 mA) and may have
blunted the response in ANTHEM-HF (16) (2.0 mA).
Although higher currents were achieved with the cuff
electrode used in the present study, this hypothesis
was not supported by our study as the primary
outcome did not improve with VNS.
The improved 6-min hall walk distance, NYHA
functional class, and quality-of-life scores with VNS
in the present study may potentially be interesting,and these measures have been associated with
favorable outcome in patients with HF (30). However,
these findings must be interpreted with caution given
that they were secondary endpoints and may be
subject to bias. Whether these outcomes are due to a
“placebo” effect in an unblinded trial or true benefits
of VNS will require further study. However, it is
noteworthy that quality of life (albeit assessed with a
different questionnaire) was also improved with VNS
in NECTAR-HF (15). The failure of VNS to reduce the
primary composite endpoint coupled with the
nonsignificant effect on LVESVi in our trial is
consistent with other HF therapies which show a clear
association between clinical outcomes and reverse LV
remodeling. Specifically, HF hospitalization rates and
mortality typically improve when LV remodeling oc-
curs with therapy (31,32).
The subgroup analyses of this trial showed only 1
significant interaction, with a worse outcome in fe-
male patients. Although this may be a concerning
result, the marked difference in clinical characteris-
tics may account for the observed findings as sup-
ported by the multivariate analysis. Further analysis
will be needed to assess if subgroups can be identified
that appear to benefit or be harmed by VNS, which
will help generate hypotheses for further study.
However, all subgroup analyses must be interpreted
cautiously even if pre-defined, as they are under-
powered statistically.
The mixed results from INOVATE-HF and previous
VNS studies (14–16) has also been noted with other
device therapies in HF such as spinal cord stimulation
(17,18). This probably illustrates the complexity of
autonomic modulation with many different factors
that may affect outcomes, including trial design,
stimulation parameter (such as site, frequency, and
intensity), and patient population under study
(13,33).
CONCLUSIONS
The INOVATE-HF trial was the first large, randomized
trial of device-based autonomic modulation in HF.
The results of the study show that VNS did not
improve the risk of death or HF events among pa-
tients with HF and a reduced LVEF.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1: VNS
was shown in pre-clinical and small observational studies
to improve heart function, quality of life, and exercise
capacity.
COMPETENCY IN MEDICAL KNOWLEDGE 2: VNS
improved quality of life, functional status, and 6-min
walk time in chronic HF but it did not promote reverse
remodeling.
TRANSLATIONAL OUTLOOK: Further study is needed
to determine if specific subgroups or stimulation proto-
cols benefit or are harmed by VNS. Moreover, additional
research is needed to determine the optimal delivery of
this therapy, including site, frequency, and strength of
stimulation.
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